Familial hyperproinsulinemia is an autosomal dominant defect that is associated with strikingly elevated levels of serum proinsulin-like material. Our studies show that trypsin converts familial hyperproinsulinemia proinsulin to insulin more slowly than it converts a 1311-labeled porcine proinsulin marker. Molar yields of insulin indicated that the material may be an intermediate proinsulin. Studies with two human C-peptide antisera that differ in their relative immunoreactivity with human C-peptide and proinsulin showed that the two antisera reacted equally with familial hyperproinsulinemia proinsulin, suggesting that it is a partially cleaved proinsulin intermediate. Sulfitolysis of highly purified material to break the inter-and intra-chain disulfide bridges and subsequent adsorption on a specific B-chain antibody covalently bound to Sepharose beads showed that the C-peptide was still connected to the B-chain. These data indicate that familial hyperproinsulinemia proinsulin is normally cleaved at the C-peptide-A-chain linkage site.
Familial hyperproinsulinemnia (FH) is a genetic defect (1) that is associated with strikingly elevated levels of serum proinsulin-like material (PLM). The PLM constitutes a major fraction (74-91%) of the total circulating immunoreactive insulin in both the fasted and stimulated states. The defect is present in members of four generations of the kindred, ranging in age from 6 months to 73 years, and is transmitted as an autosomal dominant trait. The affected progeny are asymptomatic with no apparent increase in susceptibility to hyperglycemia or the development of diabetes mellitus, suggesting that the high circulating levels of PLM contribute to the maintenance of normal carbohydrate tolerance.
We report the partial characterization of the circulating PLM in familial hyperproinsulinemia, which demonstrates that the PLM is a partially cleaved proinsulin intermediate. The structural abnormality resides at the cleavage site linking the B-chain to the C-peptide and impairs the complete conversion of familial hyperproinsuliinemia proinsulin to insulin within the beta cells of affected individuals.
METHODS
Patient Material. Plasma (400-500 ml) was obtained by plasmapheresis from two males and one female with the defect (11-9, 111-8, and 111-29 in ref. 1). The study was approved by the Clinical Investigation Committee at Children's Hospital Medical Center, and informed consent was obtained.
The levels of PLM and insulin in samples were determined by column chromatography. In the trypsin conversion studies, plasma (0.5 ml) was applied to a 1 X 50 cm column of Bio-Gel
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P-30 (Bio-Rad), equilibrated in borate/bovine serum albumin (0.5%) (BBSA) buffer, pH 8.0, to separate the PLM and insulin. Fractions (1 ml) were collected and immunoreactive insulin in each was determined by radioimmunoassay. Larger quantities of FH-PLM were prepared by chromatography of 100 ml of plasma on a 5 X 100 cm column of Sephadex G-50, fine (Pharmacia), equilibrated in 0.05 M ammonium carbonate, pH 7 .9. Fractions of 10 ml were collected and l-ml aliquots were assayed for immunoreactive insulin. The FH-PLM peak was pooled, lyophilized, and stored at -30o C until use.
Highly purified FH-PLM was prepared by extraction of the partially purified and lyophilized FH-PLM region (from a 100-ml column run) with 2 mM HCI. The extract was lyophilized and redissolved in 20 ml of BBSA buffer and recirculated through a 0.5-ml column of guinea pig anti-insulin globulin coupled to Sephatose 4B beads (see below). Approximately 90% of the FH-PLM was bound to the antibody-Sepharose during a 5-hr recirculation at room temperature. The beads were washed with 50 ml of phosphate buffered saline, and the FH-PLM was eluted from the beads with 0.1 M glycine/0.05 M HCI. The glycine was removed by chromatography of the eluate on a 1 X 25 cm column of Bio-Gel P-2, equilibrated with 0.05 M ammonium carbonate buffer. The purified FH-PLM was lyophilized and stored for use in subsequent studies.
Trypsin Conversion Studies. Conversion of purified porcine proinsulin was studied by incubation of 10-ng samples of porcine proinstilin and '311-labeled porcine proinsulin (porcine 131I-proinsulin) (20,000 cpm) in 0.5 ml of 0.1 M Tris-HCl, pH 8.3/2 mM NaCl (Tris/NaCl buffer) containing 0.1% albumin.
The mixture was shaken in a 370C waterbath, appropriate dilutions of a stock solution (1.0 mg/ml) of diphenIyl carbamyl chloride-treated trypsin (Sigma) were added to each sample, and the incubation was allowed to proceed for various time periods. The tryptic action was stopped by placing the samples on ice and adding 100-fold excess of soybean trypsin inhibitor (Worthington). The conversion of PLM in the patient's plasma was performed by adding trypsin directly to 0.5 ml of plasma containing known amounts of PLM and insulin (determined by column chromatography and radioimmmunoassay) and 20,000 cpm of porcine '3II-proinsulin. The conversion of the partially purified lyophilized FH-PILI was studied by dissolving known amounts of lyophilized FH-PLM and 20,000 cpm of porcine '311-proinsulin in 0.5 ml of Tris/NaCl buffer, and then adding various amounts of trypsin to the mixture. After addition of the trypsin inhibitor, the reaction mixture was chromatographed on a 1 X 50 cm Bio-Gel P-30 column and 1-ml fractions were collected. The A solution of 8 M urea (Schwarz/Mann; Ultra Pure) was passed through a 10-ml packed column of Amberlite MB-3 ion exchange resin (Mallinckrodt). Sufficient amounts of potassium phosphate salts were then added to make an 8 M urea/0.05 M potassium phosphate buffer, pH 7.5. The respective proinsulin materials were lyophilized in test tubes, and 7.0 mg of sodium tetrathionate (kindly prepared by Clyde Zalut, Division of Immunology, Children's Hospital Medical Center, Boston, MA) and 14 mg of sodium sulfite were added. Urea buffer (400 Ml) was added, and the mixture was shaken until dissolved and then incubated for 3 hr in a 370C waterbath. The reaction mixture was then chromatographed on a 1 X 25 cm Bio-Gel P-2 column equilibrated with 0.05 M ammonium carbonate, and 0.9-ml fractions were collected. The fractions corresponding to the total elution volume of blue dextran were collected and lyophilized for use in subsequent studies.
Coupling of Antibodies to Sepharose Beads. Guinea pig anti-bovine insulin serum was kindly donated by Peter Wright (Indiana Univ. School of Medicine, Indianapolis, IN) (Lot 570, 50% binding capacity = 1.3 units of insulin per ml). An equal volume of cold, saturated ammonium sulfate solution was added to 0.5 ml of serum, and the resulting globulin precipitate was separated by centrifugation, redissolved, dialyzed, and used for binding to Sepharose 4B beads. The anti-insulin globulin (9.6 mg) was coupled to an 8-ml gel bed volume of cyanogen bromide-activated Sepharose 4B beads and the mixture was stirred overnight at 4VC. Glycine (20 mM) was then added to react with the remaining activated Sepharose bead sites. The beads were then washed extensively with phosphate-buffered saline and stored in phosphate-buffered saline containing 0.01% merthiolate, penicillin, and streptomycin. Guinea pig antibovine insulin B-chain antibody was coupled directly to cyanogen bromide-activated Sepharose 4B beads by using 0.1 ml of the antiserum and a 10-ml gel bed volume according to the above method.
Radioimmunoassays. Insulin immunoreactivity was measured by a modification (2) of the double antibody method of Morgan and Lazarow (3) . Two guinea pig anti-bovine insulin sera, which were gifts from Lillian Recant and Peter Wright (Lot 496), were used in the assays. The two antisera are virtually identical in their properties and immunoreactivity with human and porcine proinsulin and insulin. Human insulin is 4-5 times more immunoreactive than humati proinsulin on a molat basis in the assay system used, and standard curves describing their relative immunoreactivity were published (2) . Similar relative molar ratios of immunoreactivity exist between porcine insulin and proinsulin. Intermediate porcine proinsulins [desdipeptide proinsulin, desnonapeptide (C55_3 absent) proinsulin, and "split" (LeuI4-Ala55 split) proinsulini are intermediate in their immunoreactivity in this assay system, being 2-2.5 times more immunoreactive than intact porcine proinsulin. Intermediate human proinsulins are not available for direct comparison with human insulin and proinsulin.
Guinea pig anti-bovine insulin B-chain serum was a gift from P. T. Varandani (Fels Research Institute, Yellow Springs, OH) (Lot VI-p45-15-27). Characterization of this antibody to the B-chain of insulin is presented in Results. The radioimmunoassay for B-chain was performed by the same double antibody immunoassay used for insulin with the antibody used at a final dilution in the assay tubes of 1: 180,000. Pure S-sulfonated bovine B-chain was used to prepare standards as well as 1251-Bchain label.
C-peptide immunoreactivity was determined by the double antibody radioimmunoassay technique as described (4 Porcine proinsulin conversion. Porcine proinsulin (10 ng) and 20,000 cpm of porcine '311-proinsulin were incubated with trypsin (0.5,ug/ml) for 2, 4, 10 and 15 min and then subjected to gel filtration (Fig. 1 top) . At each time point, the extent of conversion of immunoreactive porcine proinsulin to insulin was similar to the extent of conversion of porcine 1311-proinsulin to 1311-insulin. The molar yield of insulin at each time period corresponded to the amount of converted proinsulin material and averaged 0.89-i.e., the conversion was approximately stoichiometric.
Familial hyperproinsulinemia plasma conversion. FH plasma (0.5 ml) containing known amounts of FH-PLM and insulin was incubated with 20,000 cpm of '31I-proinsulin and trypsin (20 ,ug/ml or 50 ,ug/ml) for various time periods followed by gel filtration (Fig. 1 middle) . The conversion of FH-PLM present in plasma was markedly retarded as compared to the conversion of porcine 1311-proinsulin. The molar yield of insulin at the various time points averaged approximately one-half of that expected from the amount of converted FH-PLM (mean molar yield = 0.58).
Partially purified FH-PLM conversion. FH-PLM (estimated against a human intact proinsulin standard) and 20,000 cpm of '311-proinsulin were incubated with trypsin followed by gel filtration (Fig. 1 bottom) . Again, the conversion of partially purified FH-PLM was considerably slower than the conversion of porcine 1311-proinsulin. With increasing concentrations of trypsin or longer incubation times, FH-PLM can be completely converted to insulin-e.g., 90% conversion at a trypsin con- Immunoreactivity of FH-PLM with C-Peptide Antisera. Familial hyperproinsulinemia plasma (2 ml) was chromatographed on a 1.5 X 75 cm Bio-Gel P-30 column equilibrated with 3 M acetic acid to separate the PLM and C-peptide present in the plasma. Aliquots of each fraction were dried under reduced pressure and assayed for C-peptide immunoreactivity with two antisera to human C-peptide (Fig. 2) .
Due to the high PLM content of familial hyperproinsulinemia plasma, the PLM constitutes a larger proportion of the total C-peptide immunoreactivity than in normal subjects. As expected, both antisera reacted equally with the C-peptide peak. However, the two antisera that have different reactivity with intact human proinsulin reacted equally with FH-PLM. In normal sera, the PLM component reacts much less well with one antiserum than the other. These Fic.. 2. Bio-Gel P-30 column chromatography of 2 ml of familial hyperproinsulinemia plasma. The FH-PLM (first peak) and C-peptide (second peak) were assayed with two antisera to human C-peptide that differ in their relative immunoreactivity with human proinsulin. Note identical immunoreactivity of FH-PLM peak with both antisera.
-, Antiserum Y; ., antiserum M 1230.
Localization of Structural Defect in Familial Hyperproinsulinemia Proinsulin. The previous experiments suggested that FH-PIM may be a two-chain proinsulin intermediate cleaved at one linkage site, and possessing a structural defect at the other linkage site rendering it less susceptible to trypsin cleavage. The two cleavage sites in proinsulin are between the Arg-Glv residues connecting the C-peptide to the A-chain and the Arg-Glu residues connecting the B-chain to the C-peptide. A strategy was evolved to localize the defective cleavage site, based on the fact that the two chains in intermediate proinsulin (like insulin) are held together by disulfide bridges. Sulfitolysis of highly purified FH-PLM to break the disulfide bridges would result in two chains with the following possible alternate compositions: (i) an A-chain.C-peptide fragment and a free B-chain, or (ii) a B-chain-C-peptide fragment and a free A-chain. These two possible outcomes can be distinguished by adsorption of the S-sulfonated FH-PLM on B-chain antibody coupled to Sepharose beads and assaying the supernatant for C-peptide, as well as assaying the eluate from anti-B chain/Sepharose beads for the presence of both B-chain and C-peptide immunoreactivity. In order to perform this experiment, it became necessary to thoroughly characterize the B-chain antiserum and the B-chain antibody coupled to Sepharose beads.
Characterization of B-Chain Antiserum. Fig. 3 demonstrates the radioimmunoassay curves, using the guinea pig anti-bovine insulin B-chain serum. Porcine insulin, desdipeptide proinsulin, desnonapeptide proinsulin, and "split" proinsulin were approximately 2.5 times less immunoreactive than the bovine B-chain on a molar basis. Intact beled peptide to a 30-Ml gel bed of Sepharose beads in 1 ml of BBSA buffer and mixing on a rotator for 2 hr at room temperattire. The mixtures were centrifuged and the supernatants were separated. Table 1 shows that the anti-B-chain-Sepharose beads bind 77% of the insulin label, 66% of the B-chain label, and 33% of the labeled B-chain-C-peptide fragment. Importantly, the '25I-A-chain and '251-C-peptide were not bound to the beads. Incubations with normal nonimmune guinea pig serum bound to Sepharose beads showed virtually no binding of any of the labeled peptides.
Localization of Defect in Familial Hyperproinsulinemia Proinsulin. Highly purified FH-PLM was isolated by using anti-insulin-Sepharose beads. The total isolated material assayed 500 microunits when read on a human insulin standard, or 100 ng of proinsulin on the intact human proinsulin standard. On the assumption that the material represented an intermediate proinsulin, the isolated material would be equivalent to 50 ng in actual mass (see above). Aliquots of 20 ng each were lyophilized and subjected to sulfitolysis in two separate experiments. The sulfonated material was desalted by chromatography-on a Bio-Gel P-2 column, lyophilized, and redissolved in 1 ml of BBSA buffer. An mixture was centrifuged and the supernatant was removed for radioimmunoassay. Neither B-chain nor C-peptide was found in the supernatant ( Table 2 ), suggesting that both fragments were removed from the mixture by the anti-B-chain-Sepharose beads. The anti-B-chain-Sepharose beads were then washed with two portions of 2 ml of BBSA buffer, and the washes were discarded. The. bound material was eluted from the beads with two portions of 2 ml of glycine-HCl buffer. The eluates were combined and lyophilized, and the glycine was removed by chromatography on a Bio-Gel P-2 column in 3 M acetic acid. Appropriate aliquots of the deglycinated material were separately assayed for the presence of B-chain and C-peptide. Both B-chain and C-peptide were found in the eluate from the anti-B-chain-Sepharose beads (Table 2) indicating that the C-peptide is still attached to the B-chain. C-Peptide recoveries were greater than 90% of the expected amounts calculated from the starting material. B-Chain recoveries were less than 10% of expected when calculated against a B-chain standard. However, the recovery of B-chain equivalent was 79% and 92%, respectively, in the two experiments when calculated from a porcine S-sulfonated B-chain-C-peptide fragment standard. These findings indicate the presence of an intact B-chain-C-peptide fragment in familial hyperproinsulinemia proinsulin. DISCUSSION Proinsulin is cleaved into. two components, insulin and the connecting peptide or C-peptide, by an enzymatic process within the insulin secretory vesicles in the beta cells. The converting enzymes are thought to be similar to trypsin and carboxypeptidase B, and cleave proinsulin at the sites where the C-peptide is linked to the A and B-chains (7) . Trypsin, or a trypsin-like enzyme, cleaves human proinsulin (Fig. 4) at the Arg65-Gly6 residues connecting the C-peptide to the A-chain.
The basic residues, Arg-65 and Lys-64 are subsequently cleaved from the carboxyl terminal of the C-peptide by a carboxypeptidase B-like enzyme, giving rise to desdipeptide proinsulin or intermediate proinsulin 1. Trypsin additionally cleaves proinsulin at the Arg32-Glu33 residues connecting the B-chain to the C-peptide, resulting in the formation of C-peptide and diarginyl insulin. The two basic arginine residues (Arg-32 and Arg-31) are then removed to yield insulin. In normal subjects, the secretory vesicle contents, consisting of equimolar amounts of insulin and C-peptide and a small amount of intact proinsulin as well as proinsulin intermediates, are released into the circulation. These proinsulin and insulin components can be separated on the basis of their molecular size by gel chromatography of the plasma. The proinsulin peak has been shown to be heterogeneous (8) , and consists of a mixture of intact proinsulin and desdipeptide proinsulin. The intermediate forms of proinsulin were originally isolated from crystalline bovine insulin and characterized by Steiner et al. (9) . Proinsulin intermediate I is a two-chain proinsulin cleaved at the A-chain-C-peptide linkage site and lacks the Lys-Arg sequence, and Supporting data for this inference was derived from studies using two C-peptide antisera differing in their immunoreactivity with intact proinsulin. The two antisera reacted equally with FH-PLM, indicating that FH-PLM is being recognized as a C-peptide rather than as an intact proinsulin-i.e., a twochain proinsulin intermediate that still has a portion or all of the C-peptide attached to one of the chains of insulin. Presumably, the two antisera are reacting with an exposed Cpeptide rather than an intact proinsulin, because the threedimensional structure of intact proinsulin is responsible for the variation in immunoreactivity with the different C-peptide antisera.
Additional studies of highly purified FH-PLM, isolated with a specific immunoadsorbent column, provided independent confirmation of the two-chain-intermediate nature of FH-PLM, and localized the structural defect to the site linking the B-chain to the C-peptide. Sulfitolysis of FH-PLM to break the interchain distlfide bridges (Fig. 4) 
